Fresenius Group welcomes the opportunity to contribute to this call for evidence, as the revision of the Public Procurement Directive 2014/24/EU (PPD) provides a framework for the public procurement of medicines (PPM). We are operating in a highly regulated pricing framework, which does not allow for the adjustment of prices to increasing costs (e.g. energy, transport inflation).
FRE
Fresenius
Company · Germany · EU Transparency Register 047428334069-39
4
positions filed
in the 665 files tracked
4
legislative files
of 665 tracked
3
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1210 companies & groups on this site, they rank #392 by legislative files engaged, a count of participation, not a measure of influence.
1.5
declared lobbying FTE
self-declared
€300K+
declared costs / yr (floor)
1
EP accreditations
as declared to the register
2019
in the register since
Declares membership of
- Fresenius SE & Co.KGaA and its consolidated subsidiaries are represented in a large number of associations worldwide.
- Memberships of Fresenius SE & Co.KGaA in organisations that would be relevant for the register are as follows:
- MedTech Europe →
- Pharma Deutschland e. V. →
- Bundesverband Medizintechnologie e. V. (BVmed) →
- Verband der Chemischen Industrie e.V. (VCI)
- Blood Transfusion Association →
- German Health Alliance (GHA)
- Deutsches Institut für Normung e. V. (DIN)
- Medicines for Europe →
- Specialised Nutrition Europe
- Medical Nutrition International Industry Association
- and 1 more
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Companies & groups
- Registered as
- Fresenius SE & Co.KGaA (FSE)
- Head office
- Bad Homburg, Germany
- EU office
- Brüssel
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Fresenius in PolicySpeak: request access →
Work at Fresenius? so we know who speaks for it.
Their record over time
Fresenius filed 4 positions between 6 Mar 2025 and 29 Sept 2026, across 4 of the 665 legislative files tracked here, attaching a full position paper 3 times.
2025 · 1 filed2026 · 3 filed
What they argued
Fresenius welcomes the European Commission's proposal for a Biotech Act as an important step towards strengthening Europe's biotechnology and biomanufacturing ecosystem. The proposal rightly recognises biosimilars as a strategic biotechnology industry.
The proposed regulatory frameworks (CSA2 and Digital Omnibus) aim to create stronger alignment across EU cyber regulation and to reduce duplicative administrative burdens, particularly around incident reporting and certification. At the same time, they expand requirements in key areas such as ICT supply chains, cybersecurity certification, and EU-level governance (ENISA).
Fresenius welcomes the proposed Implementing Regulation for HealthData@EU. It provides the technical framework for secure cross-border access to health data for secondary use and sets up a tool for cooperation between health data access bodies. If designed well, the system can support better public health decisions, stronger patient safety and more reliable regulatory evidence.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Fresenius next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 53.
Is this your organization?
Everything on this page comes from Fresenius’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.